Alexey A. Larionov
YOU?
Author Swipe
View article: The soil microbial methylome: A tool to explore the role of epigenetic memory in driving soil abiotic legacy effects
The soil microbial methylome: A tool to explore the role of epigenetic memory in driving soil abiotic legacy effects Open
Epigenetics is a phenomenon whereby a stable hereditable change in gene expression can occur without changing the DNA sequence. DNA methylation (the addition of a methyl group to specific nucleotides in specific DNA motifs) is the most stu…
View article: Data from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of breast carcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to endocrine therapy. Pre- and on-treatment (after 2 weeks…
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Microsoft Excel workbook containing the following gene lists and information; A) 500 most variable genes from Figure 1D, B) differentially expressed genes between ILC and IDC at baseline and 3 months of treatment using Rank Products with a…
View article: Data from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of breast carcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to endocrine therapy. Pre- and on-treatment (after 2 weeks…
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Supplementary Figure Legends
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Supplementary Figure 1. ILC-specific and IDC-specific response genes identified from breast cancer cell lines are not significantly changed in response to letrozole in patient tumours. Heatmaps (A), gene set enrichment analysis (B) and spe…
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Supplementary Figure 1. ILC-specific and IDC-specific response genes identified from breast cancer cell lines are not significantly changed in response to letrozole in patient tumours. Heatmaps (A), gene set enrichment analysis (B) and spe…
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Microsoft Excel workbook containing the following gene lists and information; A) 500 most variable genes from Figure 1D, B) differentially expressed genes between ILC and IDC at baseline and 3 months of treatment using Rank Products with a…
View article: Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy Open
Supplementary Figure Legends
View article: The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women
The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women Open
Background: Contralateral breast cancer (CBC) is associated with younger age at first diagnosis, family history and pathogenic germline variants (PGVs) in genes such as BRCA1, BRCA2 and PALB2. However, data regarding genetic factors predis…
View article: Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases
Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases Open
Renal cell carcinoma (RCC) occurs in a number of cancer predisposition syndromes, but the genetic architecture of susceptibility to RCC is not well defined. We investigated the frequency of pathogenic and likely pathogenic (P/LP) germline …
View article: Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‐type <i>TP53</i> and mutant <i>KRAS, G3BP1</i> and <i>IL7R</i>
Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‐type <i>TP53</i> and mutant <i>KRAS, G3BP1</i> and <i>IL7R</i> Open
To the Editor: Ataxia telangiectasia (A-T) is an autosomal recessive disease, characterised by progressive neurodegeneration with cerebellar ataxia, oculo-cutaneous telangiectasia, immunodeficiency, and cancer predisposition. It is caused …
View article: PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas
PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas Open
Introduction Rhabdomyosarcomas (RMS) are the most prevalent form of paediatric soft tissue sarcomas. They arise from skeletal muscle progenitor cells and are divided predominantly into two subtypes, embryonic and alveolar, with relatively…
View article: Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients Open
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (pr…
View article: Current therapies for HER2-positive metastatic breast cancer patients
Current therapies for HER2-positive metastatic breast cancer patients Open
The median survival of patients with HER2-positive metastatic breast cancer has more than doubled since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 ye…